The role of mycophenolate mofetil in kidney transplantation revisited

Transplantation Reviews

Volumn 28, Issue 1, 2014, Pages 26-31

  Maripuri, Saugar ^a   Kasiske, Bertram L ^a  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; DEVICE INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LEUKOPENIA; META ANALYSIS (TOPIC); OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGISTER; REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 84889597949     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2013.10.005     Document Type: Review

References (30)

1. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995, 60:225-232.
2. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995, 345:1321-1325.
3. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996, 61:1029-1037.
4. Allison A.C., Eugui E.M., Sollinger H.W. Mycophenolate mofetil (RS-61443): Mechanisms of action and effects in transplantation. Transplant Rev 1993, 7:129-139.
5. Sollinger H.W., Deierhoi M.H., Belzer F.O., Diethelm A.G., Kauffman R.S. RS-61443-a phase I clinical trial and pilot rescue study. Transplantation 1992, 53:428-432.
6. Deierhoi M.H., Kauffman R.S., Hudson S.L., et al. Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center. Ann Surg 1993, 217:476-482. [discussion 482-4].
7. Mathew T.H. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998, 65:1450-1454.
8. Mycophenolate mofetil in cadaveric renal transplantation. US Renal Transplant Mycophenolate Mofetil Study Group. Am J Kidney Dis 1999, 34:296-303.
9. Mycophenolate mofetil for the treatment of a first acute renal allograft rejection: The Mycophenolate Mofetil Acute Renal Rejection Study Group. Transplantation 1998, 65:235-241.
10. Pollard S.G., Lear P.A., Ready A.R., Moore R.H., Johnson R.W. Comparison of microemulsion and conventional formulations of cyclosporine A in preventing acute rejection in de novo kidney transplant patients. The U.K. Neoral Renal Study Group. Transplantation 1999, 68:1325-1331.
11. Ekberg H., Tedesco-Silva H., Demirbas A., et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357:2562-2575.
12. Remuzzi G., Lesti M., Gotti E., et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503-512.
13. Shapiro R., Jordan M.L., Scantlebury V.P., et al. A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients. Transplantation 1999, 67:411-415.
14. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000, 69:834-841.
15. Ahsan N., Johnson C., Gonwa T., et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2years. Transplantation 2001, 72:245-250.
16. Gonwa T., Johnson C., Ahsan N., et al. Randomized trial of tacrolimus+mycophenolate mofetil or azathioprine versus cyclosporine+mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003, 75:2048-2053.
17. Halloran P., Mathew T., Tomlanovich S., Groth C., Hooftman L., Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997, 63:39-47.
18. Knight S.R., Russell N.K., Barcena L., Morris P.J. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. Transplantation 2009, 87:785-794.
19. Ojo A.O., Meier-Kriesche H.U., Hanson J.A., et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000, 69:2405-2409.
20. Schnitzler M.A., Craig K.E., Hardinger K.E., Lowell J.A., Brennan D.C. Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. Nephrol Dial Transplant 2003, 18:1197-1200.
21. Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 2003, 75:1341-1346.
22. Meier-Kriesche H.U., Steffen B.J., Hochberg A.M., et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003, 3:68-73.
23. Schold J.D., Kaplan B. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. Am J Transplant 2009, 9:2067-2074.
24. Meier-Kriesche H.U., Ojo A.O., Leichtman A.B., et al. Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients. J Am Soc Nephrol 2000, 11:2366-2370.
25. Meier-Kriesche H.U., Ojo A.O., Leichtman A.B., et al. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. Transplantation 2001, 71:398-401.
26. Meier-Kriesche H.U., Morris J.A., Chu A.H., et al. Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients. Nephrol Dial Transplant 2004, 19:2864-2869.
27. Luan F.L., Schaubel D.E., Zhang H., et al. Impact of immunosuppressive regimen on survival of kidney transplant recipients with hepatitis C. Transplantation 2008, 85:1601-1606.
28. David K.M., Morris J.A., Steffen B.J., Chi-Burris K.S., Gotz V.P., Gordon R.D. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 2005, 19:279-285.
29. Pham P.T., Pham P.C. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Nephrol Dial Transplant 2012, 27:2965-2971.
30. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report 2010, Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD.